便携式医疗电子设备主要分为家用便携医疗电子设备和医用便携医疗电子设备，前者包括电子血压计、电子血糖仪、电子助听器等；后者包括便携式心电图仪、便携式多参数监护仪、便携式超声波检测仪等。

近年来，受益于中国医疗保健体系的不断完善和居民医疗健康需求的持续增加，中国便携式医疗电子市场以年均27%的速度快速增长。2009年，中国便携式医疗电子市场规模达到167亿元左右，较2006年增长106%。


家用便携式医疗电子产品因价格低廉、操作方便等优点备受市场青睐，2009年已占据整个便携式医疗电子市场的65%的份额。其中，电子血压计、电子血糖仪、数字助听器三大产品的市场份额已超过90%。

在电子血压计市场，日资品牌凭借先入为主的优势，已拥有中国70%多的市场份额，其中欧姆龙电子血压计在中国的份额已经高达65%。在外资品牌迅速扩张的同时，内资品牌也加快了发展，其中表现尤为突出的是九安医疗，其2009年电子血压计销售收入达到2.7亿元，成为中国最大的电子血压内资品牌，市场份额仅次于欧姆龙，约为15%。

在便携式血糖仪市场，强生、罗氏等外资品牌占据中国市场的半壁江山，怡成、三诺等内资品牌尾随其后。其中强生牌血糖仪在中国已稳居榜首，约为45%，罗氏血糖测试设备在全球占据31%的份额，在中国也有25%的份额；怡成在激烈的竞争中，将目标市场锁定在二三线城市，现已跻身国内血糖仪市场第三。

水清木华研究中心发布的《2010年中国便携式医疗电子设备行业研究报告》，从中国便携式医疗电子设备市场整体状况出发，除了分析电子血压计、便携血糖仪等家用产品外，还重点研究了便携式超声诊断仪、植入式心脏起搏器、便携式心电图机等医用产品等。

在便携式超声诊断仪中，应用最广泛的是便携式B超仪，其销量和出口量近4年来一直以16.7%和15.4%速度增长。迈瑞作为中国便携式B超仪的领军者，2004年成功推出中国第一台全数字化便携式超声诊断仪；2006年又成功研制出中国第一台拥有完全自主知识产权的全数字彩色多普勒超声诊断仪。

与美国、日本等国家相比，中国的心脏起搏器植入量水平很低。随着中国心脏起搏器国产化水平的提高以及医疗改革进程的加快，近年中国心脏起搏器植入量以年均15%的速度增长，2003年植入量为1.4万台，2006年为2.3万台，2009年达到3.6万台左右。

在此基础上，该报告分析了欧姆龙、爱德华、强生、罗氏、美敦力、日本光电等外资龙头的运营情况及在华发展状况，并介绍了九安医疗、怡成、迈瑞等具有竞争优势的内资企业的现状、竞争优势、发展战略等。

---

Portable medical electronic devices can be mainly divided into home type and professional type, of which, the former covers electronic sphygmomanometer, electronic blood glucose meter, electronic hearing aids, etc., and the latter includes portable electrocardiograph, portable multi-parameter monitor, portable ultrasonic tester, etc.

Benefiting from the constant improvement of Chinese medical care system and the continuously increased demand for health care from the residents during recent years, China’s portable medical electronics market has experienced substantial growth with an annual average speed of 27%. In 2009, the market size of Chinese portable medical electronics approximated RMB16.7 billion, up 106% from 2006.


Home portable medical electronics have been well embraced by the market because of their superiorities such as low price and easy operation. In 2009, they enjoyed 65% shares of the entire portable medical electronics market, hereinto, electronic sphygmomanometer, electronic blood glucose meter, and digital hearing aids accounted for over 90% of the home portable medical electronics market.

In the Chinese market of electronic sphygmomanometer, Japanese brands have seized above 70% market shares due to the pioneer advantage, of which, Omron has possessed a market share as high as 65%. Domestic brands have also accelerated their development along with the rapid expansion of foreign brands. Having become the largest domestic brand of electronic sphygmomanometer, Andon Health has obtained outstanding achievements with the revenue of electronic sphygmomanometer reaching RMB270 million in 2009 and the market share neighboring 15% which was only second to that of Omron.  

As for the market of portable blood glucose meter in China, overseas brands such as Johnson & Johnson and Roche occupy half of the Chinese market, followed by domestic brands like Yicheng and Sinocare. Johnson & Johnson blood glucose meter has been stably in the first position in Chinese market with the market share of about 45%; Roche blood glucose monitor holds 31% of the global market share as well as 25% market share in China; while Yicheng aims at second and third-tier cities against the fierce competition and it has now ranked the third in the domestic market.  

Based on the overall situation of Chinese portable medical electronic device market, this report not only underlines the home products like electronic sphygmomanometer and portable blood glucose meter but also probes into the professional products such as portable ultrasonic tester, implantable cardiac pacemaker, and portable electrocardiograph.

The most widely applied portable ultrasonic tester goes to portable B-ultrasonic scanner whose sales volume and export volume have maintained respective growth rate of 16.7% and 15.4% in recent 4 years. As the leading enterprise of portable B-ultrasonic scanner in China, Mindray successfully launched China’s first digital portable ultrasonic scanner in 2004 and developed China’s first digital portable color Doppler ultrasound scanner with completely independent intellectual property right in 2006.  

The quantity of cardiac pacemaker implantations in China is extremely small compared with that in countries like the USA and Japan. Along with the enhanced localization of cardiac pacemaker production as well as the progressive medical reform, the quantity of cardiac pacemaker implantations in China has been growing at an annual average rate of 15% in recent years, from 14,000 sets in 2003 and 23,000 sets in 2006 to approximate 36,000 sets in 2009.

Accordingly, this report casts light on the operation and development in China of leading foreign enterprises like Omron, A&D, Johnson & Johnson, Roche, Medtronic, and Nihon Kohden, as well as the status quo, competitive edges and development strategy of competitive domestic enterprises such as Andon Health, Yicheng, and Mindray.